Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB5 (adalimumab biosimilar) Usability and Safety in Rheumatoid Arthritis
NCT02565810Phase 2Completed
- Sponsor
- Samsung Bioepis
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in rheumatoid arthritis (RA), sponsored by Samsung Bioepis. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02565810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565810.